Trials / Recruiting
RecruitingNCT06538311
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
Neuromodulation of Brain Function in Alzheimer's Disease and Related Dementias
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 40 Years – 99 Years
- Healthy volunteers
- Accepted
Summary
In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI). This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI). Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Active rTMS | All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday). |
| DEVICE | Sham rTMS | All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday). |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2024-08-05
- Last updated
- 2026-02-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06538311. Inclusion in this directory is not an endorsement.